Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone acetate (Primary) ; Prednisolone; Prednisone
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Cougar Biotechnology; Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 06 Jun 2023 Results of Secondary post-hoc sub-analyses of two randomized clinical trials (NCT00887198, n = 1088 and NCT02257736, n = 982) assessing The association between antibiotics administration and outcomes in men with chemotherapy-naive metastatic castration-resistant prostate cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 01 Jun 2023 Results a Secondary Analysis of the COU-AA-302 trial assessing the receipt of prior prostate-directed LT influenced the response to first-line systemic therapy and survival in docetaxel-naive metastatic castrate-resistant prostate cancer (mCRPC) patients published in the European Urology
    • 16 May 2023 Results of meta-analysis from PROpel , PREVAIL and COU-AA-302 (AA) treatment arms, Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer, published in the European Urology Open Science
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top